SEC For	m 4																
FORM 4 UNITED				TATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Estimated average burden			3235-0287 1 0.5	
1. Name and Address of Reporting Person* Sukhtian Faisal Ghiath					2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]							eck all applic X Directo	able) r	10% Owner			
(Last) (First) (Middle) C/O OUTLOOK THERAPEUTICS, INC. 4260 US ROUTE 1					3. Date of Earliest Transaction (Month/Day/Year) 03/24/2021							. Officer (give title Other (specify below) below)					
(Street) MONMOUTH JUNCTION			08852	4.	Line) X For For							e) <mark>X</mark> Form fi	or Joint/Group Filing (Check Applicable m filed by One Reporting Person m filed by More than One Reporting rson				
(City) (State) (Zip)																	
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				sactior	ction 2A. Dee Executi		ed Date	3. Transacti Code (Ins	4. Securi Disposed tr. 5)	ecurities Acquired (A) osed Of (D) (Instr. 3, 4		5. Amour Securitie Beneficia Owned F Reported Transact	nt of s ally ollowing I ion(s)	wing (I) (Instr.		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$2.27	03/24/2021		A		20,873		(1)	03/24/2031	Common Stock	20,873	\$0.00	20,873		D		

Explanation of Responses:

1. The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Remarks:

/s/ Lawrence Kenyon, Attorney-in-Fact

03/26/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.